Xyall has developed the first fully automated tissue dissection solution that enhances the precision and efficiency of selecting high-quality tissue samples for molecular pathology testing. This technology integrates precision robotics and digital pathology to eliminate the labor-intensive, subjective processes currently used, thereby reducing the risk of error and improving throughput in personalized cancer therapy.
Funding
$12.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Selecting high-quality tissue samples for molecular pathology testing is a labor-intensive, manual process prone to subjectivity, imprecision, and potential errors. This critical step in precision medicine has not kept pace with advances in PCR and next-generation sequencing technologies.
Solution
Xyall provides a fully automated tissue dissection solution that enhances the precision and efficiency of selecting tissue samples for molecular pathology. The Xyall Tissector integrates precision robotics, digital pathology, and workflow optimization to eliminate manual processes. This approach bridges the gap between histopathology and molecular pathology, providing a platform for innovation in computational pathology with high accuracy, throughput, and quality control.
Target Audience
The primary users are molecular pathology labs and personalized cancer therapy centers seeking to improve the accuracy and efficiency of tissue sample selection.
Features
- Integrates precision robotics for automated tissue dissection
- Utilizes digital pathology for enhanced visualization and analysis
- Optimizes workflow to improve efficiency
- Provides high accuracy in tissue sample selection
- Enables high throughput processing of samples
- Ensures full quality control throughout the process